Can Big Data Crack the Brain’s Toughest Diseases?

Valinor and Renew join forces to build a vast AI-ready neurology dataset, hoping to sharpen drug discovery for Alzheimer’s, Parkinson’s, and ALS

27 Feb 2026

On February 24th two biotechnology firms announced an alliance that reflects a wider shift in drug discovery. Valinor Discovery and Renew Biotechnologies plan to assemble what they call one of the largest multi-omics datasets in neurology, spanning Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS). The aim is straightforward: reduce the risk of clinical trials and speed the search for effective treatments.

Neurology has long been among the industry’s most expensive disappointments. Brain disorders are biologically complex, poorly understood and prone to late-stage trial failures. Promising targets often falter when tested in large patient groups. As costs rise, patience shrinks.

Valinor and Renew are betting that scale and integration can change this pattern. Rather than rely on narrow biomarker panels or single time-point measurements, they intend to gather genetic, molecular and clinical data from thousands of patients over time. Tracking disease progression longitudinally may reveal subtle biological changes that precede visible decline, or explain why some patients respond to treatment while others do not.

Under the agreement, Renew will collect patient samples and conduct molecular profiling. Valinor will apply its artificial-intelligence platforms to the resulting trove, building predictive models to guide target selection and early development decisions. In theory, better models mean fewer costly failures later.

The partnership illustrates a broader industry reality: high-quality data have become strategic assets. Large, harmonised datasets can power multiple drug programmes and attract investment in a crowded field of AI-enabled biotech start-ups. Capital continues to flow toward firms that promise to turn biological complexity into computable patterns.

Yet ambition brings complications. Integrating data across clinical sites requires consistent standards and careful governance. Regulators, still shaping rules for algorithmic tools in research, will expect transparency and validation. An opaque model that predicts success is unlikely to satisfy sceptical reviewers.

If the alliance succeeds, the rewards could be substantial. Even modest improvements in target identification would lower attrition rates and shorten development timelines. For patients with degenerative brain diseases, conditions with few effective treatments, that would matter greatly.

For now, the project is a wager: that more data, properly analysed, can succeed where decades of incremental advances have struggled. In neurology, optimism has often proved premature. This time, the numbers may finally be large enough to shift the odds.